HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Human epidermal growth factor receptor 2 ( HER2) is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with HER2 alterations: somatic mutations and amplifications. HER2 was first assessed as a biomarker of resistance to anti- EGFR therapy; however, in more recent years, its role as a potential actionable target has emerged. In this article, we discuss the predictive and prognostic value of HER2 in metastatic colorectal cancer, its emerging role as an actionable therapeutic target, and its possible future developments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, HER2 is commonly amplified or overexpressed in 7% to 47.4% of CRC patients, activating downstream signaling in a similar manner [81–83].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [83]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Self-citation
Research works printed but not linked: 10
- Laurent-Puig P, 2016, Ann Oncol, 27, Vi151
- Edenfield WJ, 2014, J Clin Oncol, 32
- Strickler JH, 2021, J Clin Oncol, 39
- Cavanna L, 2018, Oncol Lett, 15, 5787
- Clark JW, 2003, Onkologie, 26, 13
- Messersmith WA, 2019, J Natl Compr Cancer Netw, 17, 599
- Yoshino T, 2021, J Clin Oncol, 39
- Raghav KPS, 2021, J Clin Oncol, 39
- Li W, 2022, J Clin Oncol, 40
- Siena S, 2016, J Clin Oncol, 34
Cited by
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 669
Liquid biopsy epigenomic profiling for cancer subtyping
Baca, S. C., Seo, J.-H., Davidsohn, M. P., Fortunato, B. J., Semaan, K., Sotudian, S., Lakshminarayanan, G., Dióssy, M., Qiu, X., Zarif, T. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02605-z · Cited by 145
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“In fact, Cells 2024 , 13 , 245 9 of 16 the tucanitinib/trastuzumab combination was the topic of the MOUNTAINEER trial [70].”
BackgroundRubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Guaqueta, D. C., Naraine, A. M., & Ergle, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021064 · Cited by 85
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
Valenza, C., Guidi, L., Battaiotto, E., Trapani, D., Bianchi, A. S., Siena, S., & Curigliano, G. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.001 · Cited by 78
Metadata
- Authors
- Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S.
- Affiliations
- Medical Oncology Unit 3, Veneto Institute of Oncology IRCCS, Padua, Italy
- Istituto Oncologico Veneto (IT)
- University of Padua (IT)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 219-232
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280492853
- Cited by
- 95
- References
- 75
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 34 · 2023: 17 · 2022: 7
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2, metastatic colorectal cancer, HER2 mutation, HER2 amplification, predictive biomarkers, prognostic factors, anti-EGFR therapy resistance, targeted therapy, therapeutic target
- MeSH terms
- Humans, Prognosis, Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. https://app.cochat.ai/papers/10.1200/edbk_351354
- The paper
- Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022). HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_351354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.